Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

On Monday, Vertex Inc (VERX) stock saw a decline, ending the day at $49.29 which represents a decrease of $-2.70 or -5.19% from the prior close of $51.99. The stock opened at $50.35 and touched a low ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Scotiabank’s price target suggests a potential ... Finally, Ipswich Investment Management Co. Inc. increased its stake in Vertex Pharmaceuticals by 2.7% in the 3rd quarter.

Morgan Stanley’s price target indicates a potential ... Finally, Ipswich Investment Management Co. Inc. lifted its position in shares of Vertex Pharmaceuticals by 2.7% during the third quarter.

The 12-month price targets assessed by analysts reveal further insights ... Stay informed and make strategic decisions with our Ratings Table. Vertex Inc is a provider of tax technology and services.

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX ... The shares were purchased at a price of $38.51, marking a strategic addition to Vanguard's diverse investment portfolio.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Vertex's estimated fair value is US$75.54 based on 2 Stage Free Cash Flow to Equity Vertex is estimated to be 43% undervalued based on current share price of ... of Vertex, Inc. (NASDAQ:VERX ...